JP7352542B2 - 運動失調を処置するためのリルゾールプロドラッグの使用 - Google Patents

運動失調を処置するためのリルゾールプロドラッグの使用 Download PDF

Info

Publication number
JP7352542B2
JP7352542B2 JP2020526149A JP2020526149A JP7352542B2 JP 7352542 B2 JP7352542 B2 JP 7352542B2 JP 2020526149 A JP2020526149 A JP 2020526149A JP 2020526149 A JP2020526149 A JP 2020526149A JP 7352542 B2 JP7352542 B2 JP 7352542B2
Authority
JP
Japan
Prior art keywords
ataxia
patient
administered
riluzole
medicament according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020526149A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021502392A5 (https=
JP2021502392A (ja
Inventor
ブラディミア・コリック
ロバート・バーマン
メリッサ・バイナー
ギルバート・リタリエン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biohaven Therapeutics Ltd
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66438598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7352542(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of JP2021502392A publication Critical patent/JP2021502392A/ja
Publication of JP2021502392A5 publication Critical patent/JP2021502392A5/ja
Priority to JP2023149803A priority Critical patent/JP2023175823A/ja
Application granted granted Critical
Publication of JP7352542B2 publication Critical patent/JP7352542B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020526149A 2017-11-12 2018-11-11 運動失調を処置するためのリルゾールプロドラッグの使用 Active JP7352542B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023149803A JP2023175823A (ja) 2017-11-12 2023-09-15 運動失調を処置するためのリルゾールプロドラッグの使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762584856P 2017-11-12 2017-11-12
US62/584,856 2017-11-12
US201862717948P 2018-08-13 2018-08-13
US62/717,948 2018-08-13
PCT/US2018/060232 WO2019094851A1 (en) 2017-11-12 2018-11-11 Use of riluzole prodrugs to treat ataxias

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023149803A Division JP2023175823A (ja) 2017-11-12 2023-09-15 運動失調を処置するためのリルゾールプロドラッグの使用

Publications (3)

Publication Number Publication Date
JP2021502392A JP2021502392A (ja) 2021-01-28
JP2021502392A5 JP2021502392A5 (https=) 2021-10-21
JP7352542B2 true JP7352542B2 (ja) 2023-09-28

Family

ID=66438598

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020526149A Active JP7352542B2 (ja) 2017-11-12 2018-11-11 運動失調を処置するためのリルゾールプロドラッグの使用
JP2023149803A Pending JP2023175823A (ja) 2017-11-12 2023-09-15 運動失調を処置するためのリルゾールプロドラッグの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023149803A Pending JP2023175823A (ja) 2017-11-12 2023-09-15 運動失調を処置するためのリルゾールプロドラッグの使用

Country Status (26)

Country Link
US (3) US20210023061A1 (https=)
EP (4) EP4483956B1 (https=)
JP (2) JP7352542B2 (https=)
KR (2) KR20200103658A (https=)
CN (1) CN112292127A (https=)
AU (1) AU2018364749C1 (https=)
BR (1) BR112020009173A2 (https=)
CA (1) CA3082096A1 (https=)
DK (2) DK3706739T3 (https=)
ES (1) ES2996892T3 (https=)
FI (2) FI3706739T3 (https=)
HR (1) HRP20241675T1 (https=)
HU (1) HUE070302T2 (https=)
IL (1) IL274532B2 (https=)
LT (2) LT3706739T (https=)
MD (1) MD3706739T2 (https=)
MX (2) MX2020004678A (https=)
PH (1) PH12020550583A1 (https=)
PL (1) PL3706739T3 (https=)
PT (2) PT3706739T (https=)
RS (1) RS66277B1 (https=)
SG (1) SG11202004332XA (https=)
SI (1) SI3706739T1 (https=)
SM (1) SMT202500022T1 (https=)
WO (1) WO2019094851A1 (https=)
ZA (1) ZA202002626B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016140879A1 (en) 2015-03-03 2016-09-09 Biohaven Pharmaceutical Holding Company Ltd. Riluzole prodrugs and their use
US12295942B2 (en) 2015-03-03 2025-05-13 Biohaven Therapeutics Ltd. Riluzole prodrugs and their use
WO2018031707A1 (en) 2016-08-10 2018-02-15 Biohaven Pharmaceutical Holding Company Ltd. Acyl benzo[d]thiazol-2-amine and their methods of use
EP4277624B1 (en) * 2021-01-18 2026-01-14 Biohaven Therapeutics Ltd. Troriluzole for use in the treatment of alzheimer's disease of mild severity
US20250127789A1 (en) * 2021-11-04 2025-04-24 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing
WO2023230451A2 (en) * 2022-05-23 2023-11-30 Biohaven Therapeutics Ltd. Methods of treating spinocerebellar ataxias
WO2026078657A1 (en) 2024-10-10 2026-04-16 Biohaven Therapeutics Ltd. Prodrugs of riluzole

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016140879A1 (en) 2015-03-03 2016-09-09 Biohaven Pharmaceutical Holding Company Ltd. Riluzole prodrugs and their use

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
ATE208615T1 (de) 1993-07-09 2001-11-15 Scherer Corp R P Verfahren zur herstellung von gefriergetrockneten arzneistoffdosierungsformen
US5457895A (en) 1993-10-01 1995-10-17 R. P. Scherer Corporation Method of identifying freeze-dried dosage forms
US5837287A (en) 1994-10-28 1998-11-17 R P Scherer Corporation Process for preparing solid pharmaceutical dosage forms
WO1998036738A1 (en) 1997-02-20 1998-08-27 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
PT1001748E (pt) 1997-07-25 2006-08-31 Alpex Pharma Sa Um processo para a preparacao de um granulado adequado para a preparacao de comprimidos rapidamente desintegraveis na boca
FR2774592B1 (fr) * 1998-02-06 2000-03-17 Rhone Poulenc Rorer Sa Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet
IL143197A0 (en) 1998-11-20 2002-04-21 Rtp Pharma Inc Dispersible phospholipid stabilized microparticles
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
US6284270B1 (en) 1999-08-04 2001-09-04 Drugtech Corporation Means for creating a mass having structural integrity
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US6814978B2 (en) 2000-12-29 2004-11-09 Mcneil-Ppc, Inc. Process for preparing a soft tablet
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
ES2292848T3 (es) 2001-10-12 2008-03-16 Elan Pharma International Limited Composiciones que tienen una combinacion de caracteristicas de liberacion inmediata y liberacion controlada.
AU2003211051A1 (en) 2002-02-13 2003-09-04 Michael K. Weibel Drug dose-form and method of manufacture
ATE337003T1 (de) * 2003-04-28 2006-09-15 Biofrontera Bioscience Gmbh Verwendung von riluzole kombiniert mit geeigneten hilfs-und zusatzstoffen zur behandlung von krankheiten, die durch eine hyperproliferation von keratinozyten gekennzeichnet sind, insbesondere neurodermitis und psoriasis
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
BRPI0620578A2 (pt) 2005-12-27 2011-12-06 Jubilant Organosys Ltd composição farmacêutica que dissolve na boca e processo para o preparo da mesma
EP2170282A4 (en) 2007-06-27 2014-11-05 Hanmi Pharm Ind Co Ltd METHOD FOR PRODUCING A QUICKLY CRUSHING FORMULATION FOR ORAL ADMINISTRATION AND DEVICE FOR PREPARING AND PACKAGING THE FORMULATION
WO2009146031A1 (en) * 2008-03-31 2009-12-03 University Of South Florida Methods of treating disease-induced ataxia and non-ataxic imbalance
US8414356B2 (en) 2008-10-31 2013-04-09 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US8613937B2 (en) 2008-10-31 2013-12-24 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016140879A1 (en) 2015-03-03 2016-09-09 Biohaven Pharmaceutical Holding Company Ltd. Riluzole prodrugs and their use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIOHAVEN COMPLETES ENROLLMENT IN SPINOCEREBELLAR ATAXIA CLINICAL TRIAL WITH TRIGRILUZOLE，Biohaven Pharmaceuticals [online]，2017年05月30日，[令和4年7月19日検索]，インターネット＜URL：https://www.biohavenpharma.com/investors/news-events/press-releases/05-30-2017＞
CLINICAL TRIALS，HISTORY OF CHANGES FOR STUDY: NCT02960893/TRIAL IN ADULT SUBJECTS WITH SPINOCEREBELLAR ATAXIA，CLINICALTRIALS.GOV ARCHIVE [ONLINE]，2016年11月，P1-4，https://clinicaltrials.gov/ct2/history/NCT02960893?V_26=View
Lancet Neurol，2015年，Vol. 14，pp. 985-991

Also Published As

Publication number Publication date
HUE070302T2 (hu) 2025-05-28
US20230355592A1 (en) 2023-11-09
KR20200103658A (ko) 2020-09-02
EP4699619A3 (en) 2026-05-06
RS66277B1 (sr) 2025-01-31
US20210023061A1 (en) 2021-01-28
PH12020550583A1 (en) 2021-05-31
CA3082096A1 (en) 2019-05-16
ZA202002626B (en) 2025-02-26
LT4483956T (lt) 2026-04-27
JP2021502392A (ja) 2021-01-28
PT3706739T (pt) 2024-12-04
CN112292127A (zh) 2021-01-29
EP4483956A2 (en) 2025-01-01
MD3706739T2 (ro) 2025-02-28
SI3706739T1 (sl) 2025-03-31
US20230390252A1 (en) 2023-12-07
AU2018364749A1 (en) 2020-07-02
WO2019094851A1 (en) 2019-05-16
DK4483956T3 (da) 2026-03-23
FI4483956T3 (fi) 2026-03-16
US12102618B2 (en) 2024-10-01
IL274532A (en) 2020-06-30
DK3706739T3 (da) 2024-12-02
EP4483956A3 (en) 2025-03-19
EP4696324A3 (en) 2026-05-06
PT4483956T (pt) 2026-03-16
PL3706739T3 (pl) 2025-03-10
SG11202004332XA (en) 2020-06-29
JP2023175823A (ja) 2023-12-12
EP4696324A2 (en) 2026-02-18
EP3706739A4 (en) 2021-08-04
EP4483956B1 (en) 2025-12-31
FI3706739T3 (fi) 2024-12-27
MX2023012640A (es) 2023-11-08
EP4699619A2 (en) 2026-02-25
HRP20241675T1 (hr) 2025-02-14
EP3706739B1 (en) 2024-10-16
LT3706739T (lt) 2024-12-27
KR20250034521A (ko) 2025-03-11
NZ765220A (en) 2023-11-24
IL274532B1 (en) 2024-01-01
ES2996892T3 (en) 2025-02-13
AU2018364749C1 (en) 2024-02-15
SMT202500022T1 (it) 2025-03-12
AU2018364749B2 (en) 2023-11-09
EP3706739A1 (en) 2020-09-16
MX2020004678A (es) 2020-08-13
BR112020009173A2 (pt) 2020-11-03
IL274532B2 (en) 2024-05-01

Similar Documents

Publication Publication Date Title
JP7352542B2 (ja) 運動失調を処置するためのリルゾールプロドラッグの使用
US20190321342A1 (en) Methods of treating developmental disorders with gaboxadol
US20060122127A1 (en) Methods for reducing the side effects associated with mirtzapine treatment
HUE024558T2 (hu) Biotin alkalmazása szklerózis multiplex kezelésére
JP2021527090A (ja) 老化関連神経変性の進行および／または発症を治療および／または予防するための方法および組成物
US20240277732A1 (en) Compositions and methods for treating brain-gut disorders
Kulcu et al. Efficacy of a home-based exercise program on benign paroxysmal positional vertigo compared with betahistine
Menkes Heredodegenerative diseases
US20230372335A1 (en) TREATMENT OF COGNITIVE IMPAIRMENT WITH A CNS-PENETRANT sGC STIMULATOR
Vacchiano et al. The m. 3890G> A/MT-ND1 mtDNA rare pathogenic variant: Expanding clinical and MRI phenotypes
KR20240038980A (ko) 파킨슨병 및/또는 루이체 질환 또는 장애(들)의 치료 방법
HK40118245A (en) Use of riluzole prodrugs to treat ataxias
HK40037184A (en) Use of riluzole prodrugs to treat ataxias
HK40033906A (en) Use of riluzole prodrugs to treat ataxias
HK40033906B (en) Use of riluzole prodrugs to treat ataxias
TW200916091A (en) Neramexane for the treatment of nystagmus
EA049071B1 (ru) Применение пролекарств рилузола для лечения атаксии
CN116134048A (zh) 用于治疗神经精神障碍的组合物和方法
US20250367191A1 (en) Treatment of mitochondrial diseases with a cns-penetrant sgc stimulator zagociguat
Ng et al. Motor neuron disease: causes, classification and treatments
KR20260032577A (ko) 이보가인 치료

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20200818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210910

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210910

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220726

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230710

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230822

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230915

R150 Certificate of patent or registration of utility model

Ref document number: 7352542

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150